Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Galectin Therapeutics Inc. GALT
$1.70
-$0.06 (-3.41%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
104754205.00000000
-
week52high
2.57
-
week52low
1.02
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.43875400
-
EPS
-0.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 11:50
Описание компании
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 апр 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 13 авг 2020 г. |
| B. Riley FBR | Buy | Buy | 03 апр 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мар 2020 г. |
| B. Riley Securities | Buy | Buy | 03 апр 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LEWIS JOEL | A | 729304 | 15086 | 31 янв 2023 г. |
| Zordani Richard A. Jr. | A | 40000 | 40000 | 26 янв 2023 г. |
| Shlevin Harold H. | A | 40000 | 40000 | 26 янв 2023 г. |
| Rubin Marc | A | 40000 | 40000 | 26 янв 2023 г. |
| Schwartz Elissa J. | A | 40000 | 40000 | 26 янв 2023 г. |
| OMENN GILBERT S | A | 40000 | 40000 | 26 янв 2023 г. |
| FREEMAN KEVIN D | A | 40000 | 40000 | 26 янв 2023 г. |
| ELDRED KARY | A | 40000 | 40000 | 26 янв 2023 г. |
| AMELIO GILBERT F | A | 40000 | 40000 | 26 янв 2023 г. |
| CALLICUTT JACK W | A | 50000 | 50000 | 26 янв 2023 г. |
Новостная лента
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
GlobeNewsWire
28 ноя 2022 г. в 08:00
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6th Obesity and NASH Drug Development Summit in Boston, MA.
Galectin Therapeutics to Present in Upcoming Conferences
GlobeNewsWire
14 окт 2022 г. в 08:00
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences.
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
GlobeNewsWire
08 сент 2022 г. в 08:00
NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.
Galectin: Ability To Potentially Target Unmet Medical Need
Seeking Alpha
11 июл 2022 г. в 16:16
Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such as Pulmonary arterial hypertension, advanced NASH fibrosis, and Lung/Kidney disease.
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
GlobeNewsWire
23 мая 2022 г. в 08:00
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conference being held from May 23-26, 2022 and at the 5th Global NASH Congress in London, UK on May 26-27, 2022.